Conversely, patients with MHC‐II expression in more than 1% of tumour cells (30%) showed correlation with interferon‐γ (IFN‐γ) and IFN‐γ–mediated gene signatures, and demonstrated favourable responses to anti‐PD‐1 treatment.27 The gene discussed is IFNG; the disease is neoplasm.